...
首页> 外文期刊>International journal of oncology >Establishment and biological characterization of a novel cell line derived from hepatoid adenocarcinoma originated at the ampulla of Vater
【24h】

Establishment and biological characterization of a novel cell line derived from hepatoid adenocarcinoma originated at the ampulla of Vater

机译:源自瓦特壶腹的肝样腺癌新细胞系的建立和生物学特性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Hepatoid adenocarcinoma is a rare gastrointestinal tumor and mostly reported in the stomach. Effective chemotherapy has yet to be developed to improve poor prognosis. The present study was undertaken to establish a useful cell line derived from a hepatoid adenocarcinoma, possibly leading to a new therapeutic strategy. The new human cell line VAT-39 was established from a metastatic lymph node of a 69-year-old Japanese male patient with hepatoid adenocarcinoma of the ampulla of Vater. The primary tumor and metastatic lymph node were composed of hepatoid adenocarcinoma cells exhibiting immunohistochemical reactivity for alpha-fetoprotein (AFP) and glypican-3 (GPC3). In the metastatic lymph node, Periodic acid-Schiff (PAS) staining clarified diffuse deposition of glycogen in the cytoplasm, indicating analogous characteristics to the primary hepatoid adenocarcinoma. Moreover, VAT-39 cells produced high levels of AFP in the cultured medium, and reverse-transcriptase polymerase chain reaction (RT-PCR) verified increased expression of GPC3 mRNA in this cell line. Further, we evaluated the sensitivity to major chemotherapeutic drugs against the bile duct cancer. Neither 5-fluorouracil nor gemcitabine showed particular sensitivity to this cell line. The tumorigenicity of the cultured cells was confirmed in athymic nude mice and the histological features of the explanted tumor were similar to the VAT-39 cell line. The present VAT-39 is the first hepatoid adenocarcinoma cell line that originates from the ampulla of Vater and it will be applicable for basic biological studies searching for new strategies of molecular targeted chemotherapy to this disease.
机译:肝样腺癌是一种罕见的胃肠道肿瘤,多见于胃中。尚未开发出有效的化学疗法来改善不良预后。进行本研究以建立源自肝样腺癌的有用细胞系,可能导致新的治疗策略。新的人类细胞系VAT-39是从一名69岁的日本男性患者的转移性淋巴结建立的,该患者患有Vater壶腹肝样腺癌。原发性肿瘤和转移性淋巴结由肝样腺癌细胞组成,这些肝样细胞对甲胎蛋白(AFP)和Glypican-3(GPC3)具有免疫组织化学反应性。在转移性淋巴结中,高碘酸-希夫(PAS)染色证实了糖原在细胞质中的弥散性沉积,表明与原发性肝样腺癌的特征相似。此外,VAT-39细胞在培养基中产生高水平的AFP,逆转录聚合酶链反应(RT-PCR)证实了该细胞系中GPC3 mRNA的表达增加。此外,我们评估了对主要化疗药物对胆管癌的敏感性。 5-氟尿嘧啶和吉西他滨均未显示对该细胞系特别敏感。在无胸腺裸鼠中证实了培养细胞的致瘤性,并且植入的肿瘤的组织学特征类似于VAT-39细胞系。目前的VAT-39是第一个源自Vater壶腹的肝样腺癌细胞系,可用于基础生物学研究,以寻找针对这种疾病的分子靶向化学疗法的新策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号